Print

New ANDA Cases

Case Name

Date Filed

Judge

Drug

Patent No(s).

Takeda Pharma. Co. Ltd. v. Mylan, Inc., 12-0024 (S.D.N.Y.)

Jan. 3, 2012

Hon. Denise L. Cote

Actoplus Met® XR (pioglitazone HCl/metformin HCl extended-release)

5,965,584

6,099,859

6,166,043

6,172,090

6,495,162

6,790,459

6,866,866

7,785,627

7,919,116

7,959,946

Shire LLC v. Sandoz, Inc., 12-0040 (D. Col.)

Jan. 6, 2012

Hon. Marcia S. Krieger

Intuniv® (quanfacine hydrocholoride extended-release tablet)

5,854,290

6,287,599

6,811,794

Takeda Pharma. Co. Ltd. v. Mylan, Inc., 12-0026 (W.D. Pa.)

Jan. 6, 2012

Hon. Arthur J. Schwab

Actoplus Met® XR (pioglitazone HCl/metformin HCl extended-release)

5,965,584

6,099,859

6,166,043

6,172,090

6,495,162

6,790,459

6,866,866

7,785,627

7,919,116

7,959,946

Merck Frosst Canada & Co. v. Teva Pharma. USA Inc., 12-0210 (D.N.J.)

Jan. 11, 2012

Hon. Freda L. Wolfson

Singulair® (montelukast sodium oral granules eq. to 4 ml base/packet)

8,007,830

Meda Pharma. Inc. v. Apotex Inc., 12-0361 (D.N.J.)

Jan. 19, 2012

Hon. Peter G. Sheridan

Astepro® (azelastine hydrochloride nasal spray)

8,071,073

Abbott Labs. v. Cadila Healthcare Ltd., 12-0065 (D. Del.)

Jan. 20, 2012

Hon. Sue L. Robinson

Niaspan® (niacin extended-release tablet)

6,080,428

Spectrum Pharma. Inc. v. Sandoz Inc., 12-0111 (D. Nev.)

Jan. 20, 2012

Hon. Larry R. Hicks

Fusilev® (levoleucovorin for injection)

6,500,829

Eli Lilly & Co. v. Accord Healthcare, Inc., USA, 12-0086 (S.D. Ind.)

Jan. 20, 2012

Hon. Richard L. Young

Alimta® (pemetrexed disodium for injection)

7,772,209

Cephalon, Inc. v. Mylan Pharma. Inc., 12-0073 (D. Del.)

Jan. 24, 2012

Hon. Sue L. Robinson

Fentora® (fentanyl buccal tablet)

8,092,832

Cephalon, Inc. v. Sandoz, Inc., 12-0074 (D. Del.)

Jan. 24, 2012

Hon. Sue L. Robinson

Fentora® (fentanyl buccal tablet)

8,092,832

AstraZeneca AB v. Torrent Pharma. Ltd., 12-0506 (D.N.J.)

Jan. 26, 2012

Hon. Joel A. Pisano

Nexium® (esomeprazole magnesium delayed-release capsules)

5,714,504

5,877,192

6,875,872

Valeant Int’l (Barbados) SRL v. Spear Pharma., Inc., 12-0043 (M.D. Fla.)

Jan. 26, 2012

Hon. John E. Steele

Carac® (fluorouracil topical cream 0.5%)

6,670,335

Allergan, Inc. v. Hi-Tech Pharmacal Co., 12-0043 (E.D. Tex.)

Jan. 27, 2012

Hon. Michael H. Schneider

Lumigan® (bimatoprost ophthalmic solution, 0.01%)

7,851,504

Takeda Pharma. Co., Ltd. v. Sandoz Inc., 12-0446 (N.D. Cal.)

Jan. 27, 2012

Hon. Joseph C. Spero

Dexilant® (dexlansoprazole delayed-release capsules)

6,462,058

6,664,276

6,939,971

7,285,668

7,790,755

Abbott Labs. v. Sandoz, Inc., 12-0103 (D. Del.)

Jan. 30, 2012

Hon. Sue L. Robinson

Simcor® (niacin and simvastatin tablets)

6,080,428

6,469,035

Shire LLC v. Mylan Pharma. Inc., 12-0638 (D.N.J.)

Feb. 2, 2012

Hon. Stanley R. Chesler

Vyvanse® (lisdexamfetamine dimesylate capsule)

7,105,486

7,223,735

7,655,630

7,659,253

7,659,254

7,662,787

7,671,030

7,671,031

7,674,774

7,678,770

7,678,771

7,687,466

7,687,467

7,718,619

7,723,305

Purdue Pharma L.P. v. Sandoz Inc., 12-0897 (S.D.N.Y.)

Feb. 3, 2012

Hon. Sidney H. Stein

OxyContin® (controlled-release oxycodone)

6,488,963

7,674,799

7,674,800

7,683,072

7,776,314

Senju Pharma. Co., Ltd. v. Apotex Inc., 12-0159 (D. Del.)

Feb. 10, 2012

Hon. Sue L. Robinson

Zymaxid® (gatifloxacin ophthalmic solution 0.5%)

5,880,283

6,333,045

Merck & CIE v. Watson Pharma., Inc., 12-0161 (D. Del.)

Feb. 10, 2012

Hon. Richard G. Andrews

Beyaz® (drospirenone/ethinyl estradiol/levomefolate calcium tablets and Levomefolate calcium tablets)

6,441,168

Merck & CIE v. Watson Pharma., Inc., 12-0223 (D. Nev.)

Feb. 13, 2012

Hon. Larry R. Hicks

Beyaz® (drospirenone/ethinyl estradiol/levomefolate calcium tablets and Levomefolate calcium tablets)

6,441,168

Novo Nordisk Inc. v. Aurobindo Pharma Ltd., 12-1026 (D.N.J.)

Feb. 16, 2012

Hon. Freda L. Wolfson

Prandin® (repaglinide tablets)

6,677,358

Spectrum Pharma, Inc. v. Innopharma, Inc., 12-0265 (D. Nev.)

Feb. 17, 2012

Hon. Gloria M. Navarro

Fusilev® (levoleucovorin for injection)

6,500,829

Abbott Labs. v. Hospira, Inc., 12-0234 (D. Del.)

Feb. 27, 2012

Hon. Gregory M. Sleet

Zemplar® (paricalcitol for injection)

5,597,815

Abbott Labs. v. Amneal Pharma., LLC, 12-0235 (D. Del.)

Feb. 27, 2012

Hon. Sue L. Robinson

Niaspan® (niacin extended release tablets)

6,080,428

Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, 12-1243 (D.N.J.)

Feb. 27, 2012

Hon. Esther Salas

Cambia® (diclofenac potassium for oral solution)

8,097,651

Cephalon, Inc. v. Mylan Pharma. Inc., 12-0247 (D. Del.)

Feb. 29, 2012

Hon. Sue L. Robinson

Fentora® (fentanyl citrate buccal tablets)

8,119,158

Cephalon, Inc. v. Sandoz Inc., 12-0248 (D. Del.)

Feb. 29, 2012

Hon. Sue L. Robinson

Fentora® (fentanyl citrate buccal tablets)

8,119,158

Merck Frosst Canada & Co. v. Dr. Reddy’s Labs., Ltd., 12-1324 (D.N.J.)

Mar. 2, 2012

Hon. Freda L. Wolfson

Singulair® (montelukast sodium oral granules eq. to 4 mg base/packet)

8,007,830

Depomed, Inc. v. Actavis Elizabeth LLC, 12-1358 (D.N.J.)

Mar. 2, 2012

Hon. Joel A. Pisano

Gralise® (gabapentin extended-release tablets)

6,340,475

6,488,962

6,635,280

6,723,340

7,438,927

7,731,989

Abbott Labs. v. Mylan Inc., 12-0257 (D. Del.)

Mar. 2, 2012

Hon. Sue L. Robinson

Niaspan® (niacin extended-release tablets)

6,080,428

6,129,930

6,406,715

6,469,035

6,676,967

6,746,691

6,818,229

7,011,848

7,998,506

Avanir Pharma., Inc. v. Watson Pharma., Inc., 12-0258 (D. Del.)

Mar. 2, 2012

Hon. Leonard P. Stark

Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate capsules)

7,659,282

RE38,115

Spectrum Pharma., Inc. v. Innopharma, Inc., 12-0260 (D. Del.)

Mar. 2, 2012

Hon. Christopher J. Burke

Fusilev® (levoleucovorin)

6,500,829

AstraZeneca AB v. Mylan Labs. Ltd., 12-1378 (D.N.J.)

Mar. 6, 2012

Hon. Joel A. Pisano

Nexium® (esomeprazole magnesium capsules)

5,714,504

5,877,192

6,875,872

Avanir Pharma., Inc. v. Watson Pharma., Inc., 12-1463 (D.N.J.)

Mar. 8, 2012

Hon. William J. Martini

Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate capsules)

7,659,282

RE38,115

Genzyme Corp. v. Invagen Pharma., Inc., 12-1164 (E.D.N.Y.)

Mar. 8, 2012

Hon. Jack B. Weinstein

Renagel® (sevelamer hydrochloride tablets)

5,667,775

AstraZeneca AB v. Mylan Labs. Ltd., 12-0300 (D. Del.)

Mar. 12, 2012

Hon. Mary Pat Thynge

Nexium® (esomeprazole magnesium capsules)

5,714,504

5,877,192

6,875,872

Genzyme Corp. V. Invagen Pharma., Inc., 12-1819 (S.D.N.Y.)

Mar. 12, 2012

Hon. Jed S. Rakoff

Renagel® (sevelamer hydrochloride tablets)

5,667,775

Forest Labs., Inc. v. Torrent Pharma. Ltd., 12-0305 (D. Del).

Mar. 13, 2012

Hon. Sue L. Robinson

Bystolic® (nebivolol hydrochloride)

6,545,040

Allergan, Inc. v. Apotex, Inc., 12-0247 (M.D.N.C.)

Mar. 13, 2012

Hon. Catherine C. Eagles

Latisse® (bimatoprost ophthalmic solution, 0.03%)

8,038,988

8,101,161

Forest Labs., Inc. v. Indchemie Health Specialties Pvt. Ltd., 12-1855 (N.D. Ill.)

Mar. 14, 2012

Hon. Elaine E. Bucklo

Bystolic® (nebivolol hydrochloride)

6,545,040

United Therapeutics Corp. v. Sandoz, Inc., 12-1617 (D.N.J.)

Mar. 14, 2012

Hon. Peter G. Sheridan

Remodulin® (treprostinil sodium for injection)

5,153,222

6,765,117

7,999,007

Alkermes Pharma Ireland Ltd. v. Actavis, Inc., 12-0323 (D. Del.)

Mar. 16, 2012

Hon. Sue L. Robinson

Focalin® XR (dexmethylphenidate hydrochloride capsules)

6,228,398

6,730,325

Abbott Labs. v. Watson, Pharma., Inc., 12-0324 (D. Del.)

Mar. 16, 2012

Hon. Sue L. Robinson

Niaspan® (niacin extended-release tablet)

6,080,428

6,469,035

Celgene Corp. v. Actavis South Atlantic LLC, 12-1688 (D.N.J.)

Mar. 16, 2012

Hon. Susan D. Wigenton

Focalin® XR (dexmethylphenidate hydrochloride capsules)

5,908,850

6,355,656

6,528,530

5,837,284

6,635,284

7,431,944

Shire Development LLC v. Osmotica Pharma. Corp., 12-0904 (N.D. Ga.)

Mar. 16, 2012

Hon. Amy Totenberg

Lialda® (mesalamine delayed-release tablets)

6,773,720

Novartis Pharma. Corp. v. Actavis Group HF., 12-0366 (D. Del.)

Mar. 21, 2012

Hon. Christopher J. Burke

Exjade® (deferasirox tablets for oral suspension)

6,465,504

6,596,750

Cubist Pharma., Inc. v. Hospira, Inc., 12-0367 (D. Del.)

Mar. 21, 2012

Hon. Gregory M. Sleet

Cubicin® (daptomycin for injection)

6,468,967

6,852,689

8,058,238

RE39,071

Novartis Pharma. Corp. v. Actavis Elizabeth LLC, 12-1798 (D.N.J.)

Mar. 22, 2012

Hon. Dennis M. Cavanaugh

Exjade® (deferasirox tablets for oral suspension)

6,465,504

6,596,750

Allergan, Inc. v. Watson Labs. Inc., 12-0197 (E.D. Tex.)

Mar. 23, 2012

Hon. Michael H. Schneider

Lumigan® (bimatoprost ophthalmic solution, 0.01%)

7,851,504

5,688,819

Horizon Pharma., Inc. v. Par Pharma. Companies, 12-0393 (D. Del.)

Mar. 28, 2012

Unassigned

Duexis® (ibuprofren and famotidine)

8,067,033

Eagle Pharma., Inc. v. Sandoz, Inc., 12-1938 (D.N.J.)

Mar. 30, 2012

Hon. Peter G. Sheridan

Argatroban® (argatroban injectable)

7,589,106

7,687,516

GlaxoSmithKline PLC v. Hikma Pharma. Co., Ltd., 12-1965 (D.N.J.)

Mar. 30, 2012

Hon. Freda L. Wolfson

Argatroban® (argatroban injectable)

5,214,052

Allergan, Inc. v. Watson Pharma., Inc., 12-0321 (M.D.N.C.)

Mar. 30, 2012

Unassigned

Latisse® (bimatoprost ophthalmic solution, 0.03%)

7,351,404

7,388,029

8,038,988

6,403,649

8,017,655

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.